Epigenomics of leukemia: from mechanisms to therapeutic applications

• Dohner H , StilgenbauerS, FischerK, SchroderM, BentzM, LichterP. Diagnosis and monitoring of chromosome aberrations in hematological malignancies by fluorescence in situ hybridization. Stem Cells13(Suppl. 3) , 76–82 (1995).
   PubMed Web of Science ®Google Scholar
• Codony C , CrespoM, AbrisquetaP, MontserratE, BoschF. Gene expression profiling in chronic lymphocytic leukaemia. Best Pract. Res. Clin. Haematol.22(2) , 211–222 (2009).
   PubMed Web of Science ®Google Scholar
• Pekarsky Y , ZanesiN, CroceCM. Molecular basis of CLL. Semin. Cancer Biol.20(6) , 370–376 (2010).
   PubMed Web of Science ®Google Scholar
• Calin GA , DumitruCD, ShimizuMet al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99(24) , 15524–15529 (2002).
   PubMed Web of Science ®Google Scholar
• Zenz T , KroberA, SchererKet al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112(8) , 3322–3329 (2008).
   PubMed Web of Science ®Google Scholar
• Perrotti D , JamiesonC, GoldmanJ, SkorskiT. Chronic myeloid leukemia: mechanisms of blastic transformation. 120(7) , 2254–2264 (2010).
   Google Scholar
• Chen Y , PengC, SullivanC, LiD, LiS. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia24(9) , 1545–1554 (2010).
   PubMed Web of Science ®Google Scholar
• Mrûzek K , HarperDP, AplanPD. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol. Oncol. Clin. North Am.23(5) , 991–1010 (2009).
   PubMed Web of Science ®Google Scholar
• Martens JHA , StunnenbergHG. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett.584(12) , 2662–2669 (2010).
   PubMed Web of Science ®Google Scholar
• Hatziapostolou M , IliopoulosD. Epigenetic aberrations during oncogenesis. Cell Mol. Life Sci.68(10) , 1681–1702 (2011).
   PubMed Web of Science ®Google Scholar
• Galm O , HermanJG, BaylinSB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev.20(1) , 1–13 (2006).
   PubMed Web of Science ®Google Scholar
• Chen J , OdenikeO, RowleyJD. Leukaemogenesis: more than mutant genes. Nat. Rev. Cancer10(1) , 23–36 (2010).
   PubMed Web of Science ®Google Scholar
• Jones PA , BaylinSB. The epigenomics of cancer. Cell128(4) , 683–692 (2007).
   PubMed Web of Science ®Google Scholar
• Ting AH , McgarveyKM, BaylinSB. The cancer epigenome – components and functional correlates. Genes Dev.20(23) , 3215–3231 (2006).
   PubMed Web of Science ®Google Scholar
• Esteller M . Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet.16(Spec. No. 1) , R50–R59 (2007).
   PubMed Web of Science ®Google Scholar
• Portela A , EstellerM. Epigenetic modifications and human disease. Nat. Biotechnol.28(10) , 1057–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Straussman R , NejmanD, RobertsDet al. Developmental programming of CpG island methylation profiles in the human genome. Nat. Struct. Mol. Biol. 16(5) , 564–571 (2009).
   PubMed Web of Science ®Google Scholar
• Barakat TS , JonkersI, MonkhorstK, GribnauJ. X-changing information on X inactivation. Exp. Cell Res.316(5) , 679–687 (2010).
   PubMed Web of Science ®Google Scholar
• Wilkins JF . Genomic imprinting and methylation: epigenetic canalization and conflict. Trends Genet.21(6) , 356–365 (2005).
   PubMed Web of Science ®Google Scholar
• Goodier JL , KazazianHH Jr. Retrotransposons revisited: the restraint and rehabilitation of parasites. Cell135(1) , 23–35 (2008).
   PubMed Web of Science ®Google Scholar
• Berger SL . The complex language of chromatin regulation during transcription. Nature447(7143) , 407–412 (2007).
   PubMed Web of Science ®Google Scholar
• Kouzarides T . Chromatin modifications and their function. Cell128(4) , 693–705 (2007).
   PubMed Web of Science ®Google Scholar
• Baylin SB . DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol.2(Suppl. 1) , S4–S11 (2005).
   PubMedGoogle Scholar
• Issa JP , ZehnbauerBA, KaufmannSH, BielMA, BaylinSB. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res.57(9) , 1678–1681 (1997).
   PubMed Web of Science ®Google Scholar
• Strathdee G , HolyoakeTL, SimAet al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin. Cancer Res. 13(17) , 5048–5055 (2007).
   PubMed Web of Science ®Google Scholar
• Plass C , YuF, YuLet al. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. Oncogene 18(20) , 3159–3165 (1999).
   PubMed Web of Science ®Google Scholar
• Cameron EE , BaylinSB, HermanJG. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood94(7) , 2445–2451 (1999).
   PubMed Web of Science ®Google Scholar
• Wong IH , NgMH, HuangDP, LeeJC. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood95(6) , 1942–1949 (2000).
   PubMed Web of Science ®Google Scholar
• Asimakopoulos FA , ShteperPJ, KrichevskySet al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 94(7) , 2452–2460 (1999).
   PubMed Web of Science ®Google Scholar
• Mills KI , GuinnBA, WalshVA, BurnettAK. Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients. Leuk. Res.20(9) , 771–775 (1996).
   PubMed Web of Science ®Google Scholar
• Issa JP , ZehnbauerBA, CivinCIet al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res. 56(5) , 973–977 (1996).
   PubMed Web of Science ®Google Scholar
• San Jose-Eneriz E , AgirreX, Jimenez-VelascoAet al. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur. J. Cancer 45(10) , 1877–1889 (2009).
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J , CastillejoJA, JimenezAet al. 5´ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 99(7) , 2291–2296 (2002).
   PubMed Web of Science ®Google Scholar
• Roman J , CastillejoJA, JimenezAet al. Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome. Br. J. Haematol. 113(2) , 329–338 (2001).
   PubMed Web of Science ®Google Scholar
• Shteper PJ , SiegfriedZ, AsimakopoulosFAet al. ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR–ABL. Leukemia 15(4) , 575–582 (2001).
   PubMed Web of Science ®Google Scholar
• Montserrat E . New prognostic markers in CLL. Hematol. Am. Soc. Hematol. Educ. Program279–284 (2006).
   PubMedGoogle Scholar
• Corcoran M , ParkerA, OrchardJet al. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 90(8) , 1078–1088 (2005).
   PubMed Web of Science ®Google Scholar
• Raval A , LucasDM, MatkovicJJet al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J. Clin. Oncol. 23(17) , 3877–3885 (2005).
   PubMed Web of Science ®Google Scholar
• Irving L , Mainou-FowlerT, ParkerA, IbbotsonRE, OscierDG, StrathdeeG. Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia. Epigenetics6(3) , 300–306 (2011).
   PubMed Web of Science ®Google Scholar
• Strathdee G , SimA, ParkerA, OscierD, BrownR. Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL. Leukemia20(7) , 1326–1329 (2006).
   PubMed Web of Science ®Google Scholar
• Mizuno S , ChijiwaT, OkamuraTet al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 97(5) , 1172–1179 (2001).
   PubMed Web of Science ®Google Scholar
• Di Croce L , RakerVA, CorsaroMet al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295(5557) , 1079–1082 (2002).
   PubMed Web of Science ®Google Scholar
• Narducci MG , PescarmonaE, LazzeriCet al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res. 60(8) , 2095–2100 (2000).
   PubMed Web of Science ®Google Scholar
• Yuille MR , CondieA, StoneEMet al. TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosomes Cancer 30(4) , 336–341 (2001).
   PubMed Web of Science ®Google Scholar
• Carney DA , WierdaWG. Genetics and molecular biology of chronic lymphocytic leukemia. Curr. Treat. Options Oncol.6(3) , 215–225 (2005).
   PubMedGoogle Scholar
• Melki JR , ClarkSJ. DNA methylation changes in leukaemia. Semin. Cancer Biol.12(5) , 347–357 (2002).
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J , Jimenez-VelascoA, AgirreXet al. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24(48) , 7213–7223 (2005).
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J , Jimenez-VelascoA, AgirreXet al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica 92(2) , 153–162 (2007).
   PubMed Web of Science ®Google Scholar
• Rogers SL , ZhaoY, JiangX, EavesCJ, MagerDL, RouhiA. Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia. Mol. Cancer9 , 41 (2010).
   PubMedGoogle Scholar
• Ley TJ , DingL, WalterMJet al.DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med.363(25) , 2424–2433 (2010).
   PubMed Web of Science ®Google Scholar
• Shah MY , LichtJD. DNMT3A mutations in acute myeloid leukemia. Nat. Genet.43(4) , 289–290 (2011).
   PubMed Web of Science ®Google Scholar
• Yamashita Y , YuanJ, SuetakeIet al. Array-based genomic resequencing of human leukemia. Oncogene 29(25) , 3723–3731 (2010).
   PubMed Web of Science ®Google Scholar
• Figueroa ME , Abdel-WahabO, LuCet al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6) , 553–567 (2010).
   PubMed Web of Science ®Google Scholar
• Brecqueville M , CerveraN, Gelsi-BoyerVet al. Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. Blood Cancer J. 1 , 1–2 (2011).
   Web of Science ®Google Scholar
• Watt PM , KumarR, KeesUR. Promoter demethylation accompanies reactivation of the HOX11 proto-oncogene in leukemia. Genes Chromosomes Cancer29(4) , 371–377 (2000).
   PubMed Web of Science ®Google Scholar
• Piekarz RL , BatesSE. Epigenetic modifiers: basic understanding and clinical development. Clin. Cancer Res.15(12) , 3918–3926 (2009).
   PubMed Web of Science ®Google Scholar
• Grovdal M , KarimiM, KhanRet al. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br. J. Haematol. 150(3) , 293–302 (2010).
   PubMed Web of Science ®Google Scholar
• Khan R , Schmidt-MendeJ, KarimiMet al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp. Hematol. 36(2) , 149–157 (2008).
   PubMed Web of Science ®Google Scholar
• Schmelz K , SattlerN, WagnerM, LubbertM, DorkenB, TammI. Induction of gene expression by 5-aza-2´-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia19(1) , 103–111 (2005).
   PubMed Web of Science ®Google Scholar
• Pinto A , AttadiaV, FuscoA, FerraraF, SpadaOA, Di Fiore PP. 5-aza-2´-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood64(4) , 922–929 (1984).
   PubMed Web of Science ®Google Scholar
• Yang Q , ShanL, YoshimuraGet al. 5-aza-2´-deoxycytidine induces retinoic acid receptor β 2 demethylation, cell cycle arrest and growth inhibition in breast carcinoma cells. Anti Cancer Res. 22(5) , 2753–2756 (2002).
   PubMed Web of Science ®Google Scholar
• Schnekenburger M , GrandjenetteC, GhelfiJet al. Sustained exposure to the DNA demethylating agent, 2´-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. Biochem. Pharmacol. 81(3) , 364–378 (2011).
   PubMed Web of Science ®Google Scholar
• Martin C , ZhangY. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol.6(11) , 838–849 (2005).
   PubMed Web of Science ®Google Scholar
• Di Gennaro E , BruzzeseF, CaragliaM, AbruzzeseA, BudillonA. Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids26(4) , 435–441 (2004).
   PubMed Web of Science ®Google Scholar
• Hodawadekar SC , MarmorsteinR. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene26(37) , 5528–5540 (2007).
   PubMed Web of Science ®Google Scholar
• Close P , CreppeC, GillardMet al. The emerging role of lysine acetylation of non-nuclear proteins. Cell Mol. Life Sci. 67(8) , 1255–1264 (2010).
   PubMed Web of Science ®Google Scholar
• Hildmann C , RiesterD, SchwienhorstA. Histone deacetylases – an important class of cellular regulators with a variety of functions. Appl. Microbiol. Biotechnol.75(3) , 487–497 (2007).
   PubMed Web of Science ®Google Scholar
• Gallinari P , Di Marco S, Jones P, Pallaoro M, Steinkuhler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res.17(3) , 195–211 (2007).
   PubMed Web of Science ®Google Scholar
• Warrell RP Jr, Frankel SR, Miller WH Jr et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med.324(20) , 1385–1393 (1991).
   PubMed Web of Science ®Google Scholar
• Minucci S , CioceM, MaccaranaM, PelicciPG. The APL-associated fusion proteins. Haematologica84(Suppl. EHA-4) , 70–71 (1999).
   PubMedGoogle Scholar
• Lin RJ , EvansRM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell5(5) , 821–830 (2000).
   PubMed Web of Science ®Google Scholar
• Minucci S , NerviC, Lo Coco F, Pelicci PG. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene20(24) , 3110–3115 (2001).
   PubMed Web of Science ®Google Scholar
• Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl Cancer. Inst.90(21) , 1621–1625 (1998).
   PubMed Web of Science ®Google Scholar
• He LZ , TolentinoT, GraysonPet al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108(9) , 1321–1330 (2001).
   PubMed Web of Science ®Google Scholar
• Tickenbrock L , KleinHU, TrentoCet al. Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. Leuk. Res. 35(5) , 620–625 (2011).
   PubMed Web of Science ®Google Scholar
• Martens JH , BrinkmanAB, SimmerFet al. PML–RARα/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 17(2) , 173–185 (2010).
   PubMed Web of Science ®Google Scholar
• Bradbury CA , KhanimFL, HaydenRet al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19(10) , 1751–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Moreno DA , ScrideliCA, CortezMAet al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 150(6) , 665–673 (2010).
   PubMed Web of Science ®Google Scholar
• Advani AS , GibsonSE, DouglasEet al. Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients. BMC Cancer 10 , 387 (2010).
   PubMed Web of Science ®Google Scholar
• Di Croce L . Chromatin modifying activity of leukaemia associated fusion proteins. Hum. Mol. Genet.14(Spec. No. 1) , R77–R84 (2005).
   PubMed Web of Science ®Google Scholar
• Wang GG , AllisCD, ChiP. Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends Mol. Med.13(9) , 363–372 (2007).
   PubMed Web of Science ®Google Scholar
• Mullighan CG , ZhangJ, KasperLHet al.CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature471(7337) , 235–239 (2011).
   PubMed Web of Science ®Google Scholar
• Copeland RA , SolomonME, RichonVM. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov.8(9) , 724–732 (2009).
   PubMed Web of Science ®Google Scholar
• Tsukada Y , FangJ, Erdjument-BromageHet al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 439(7078) , 811–816 (2006).
   PubMed Web of Science ®Google Scholar
• Cloos PA , ChristensenJ, AggerK, HelinK. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev.22(9) , 1115–1140 (2008).
   PubMed Web of Science ®Google Scholar
• Hublitz P , AlbertM, PetersAH. Mechanisms of transcriptional repression by histone lysine methylation. Int. J. Dev. Biol.53(2–3) , 335–354 (2009).
   PubMed Web of Science ®Google Scholar
• Miremadi A , OestergaardMZ, PharoahPD, CaldasC. Cancer genetics of epigenetic genes. Hum. Mol. Genet.16(Spec. No. 1) , R28–R49 (2007).
   PubMed Web of Science ®Google Scholar
• Albert M , HelinK. Histone methyltransferases in cancer. Semin. Cell. Dev. Biol.21(2) , 209–220 (2010).
   PubMed Web of Science ®Google Scholar
• Hess JL . MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med.10(10) , 500–507 (2004).
   PubMed Web of Science ®Google Scholar
• Okada Y , FengQ, LinYet al. hDOT1L links histone methylation to leukemogenesis. Cell 121(2) , 167–178 (2005).
   PubMed Web of Science ®Google Scholar
• Krivtsov AV , FengZ, LemieuxMEet al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14(5) , 355–368 (2008).
   PubMed Web of Science ®Google Scholar
• Chang MJ , WuH, AchilleNJet al. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 70(24) , 10234–10242 (2010).
   PubMed Web of Science ®Google Scholar
• Nebral K , KonigM, SchmidtHHet al. Screening for NUP98 rearrangements in hematopoietic malignancies by fluorescence in situ hybridization. Haematologica 90(6) , 746–752 (2005).
   PubMed Web of Science ®Google Scholar
• Wang GG , CaiL, PasillasMP, KampsMP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat. Cell Biol.9(7) , 804–812 (2007).
   PubMed Web of Science ®Google Scholar
• Rosati R , La Starza R, Veronese A et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11) (p11. 2;p15). Blood99(10) , 3857–3860 (2002).
   PubMed Web of Science ®Google Scholar
• Simon JA . Chromatin compaction at Hox loci: a polycomb tale beyond histone tails. Mol. Cell38(3) , 321–322 (2010).
   PubMed Web of Science ®Google Scholar
• Lange CA . Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res.647(1–2) , 21–29 (2008).
   PubMed Web of Science ®Google Scholar
• Sasaki D , ImaizumiY, HasegawaHet al. Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 96(5) , 712–719 (2011).
   PubMed Web of Science ®Google Scholar
• Ernst T , ChaseAJ, ScoreJet al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42(8) , 722–726 (2010).
   PubMed Web of Science ®Google Scholar
• Marteau JB , RigaudO, BrugatTet al. Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males. BMC Med. Genomics 3 , 53 (2010).
   PubMed Web of Science ®Google Scholar
• Varier RA , TimmersHT. Histone lysine methylation and demethylation pathways in cancer. Biochim. Biophys. Acta1815(1) , 75–89 (2011).
   PubMed Web of Science ®Google Scholar
• He J , NguyenAT, ZhangY. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood117(14) , 3869–3880 (2011).
   PubMed Web of Science ®Google Scholar
• Hu X , LiX, ValverdeKet al. LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis. Proc. Natl Acad. Sci. USA 106(25) , 10141–10146 (2009).
   PubMed Web of Science ®Google Scholar
• Altucci L , ClarkeN, NebbiosoA, ScognamiglioA, GronemeyerH. Acute myeloid leukemia: therapeutic impact of epigenetic drugs. Int. J. Biochem. Cell Biol.37(9) , 1752–1762 (2005).
   PubMed Web of Science ®Google Scholar
• Leone G , D‘AloF, ZardoG, VosoMT, NerviC. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr. Med. Chem.15(13) , 1274–1287 (2008).
   PubMed Web of Science ®Google Scholar
• Marks PA . Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim. Biophys. Acta1799(10–12) , 717–725 (2010).
   PubMed Web of Science ®Google Scholar
• Prince HM , BishtonMJ, HarrisonSJ. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res.15(12) , 3958–3969 (2009).
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A , SantosFP, Garcia-ManeroG. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia25(2) , 226–235 (2011).
   PubMed Web of Science ®Google Scholar
• Zain J , O‘ConnorOA. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest. New Drugs28(Suppl. 1) , S58–S78 (2010).
   PubMed Web of Science ®Google Scholar
• Mercurio C , MinucciS, PelicciPG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol. Res.62(1) , 18–34 (2010).
   PubMed Web of Science ®Google Scholar
• Gore SD , WengLJ, ZhaiSet al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 7(8) , 2330–2339 (2001).
   PubMed Web of Science ®Google Scholar
• Batova A , ShaoLE, DiccianniMBet al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 100(9) , 3319–3324 (2002).
   PubMed Web of Science ®Google Scholar
• Chateauvieux S , MorceauF, DicatoM, DiederichM. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol.pii , 479364 (2010).
   Google Scholar
• Handoko KB , SouvereinPC, Van Staa TP et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia47(7) , 1232–1236 (2006).
   PubMed Web of Science ®Google Scholar
• Chateauvieux S , EifesS, MorceauFet al. Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway. Biochem. Pharmacol. 81(4) , 498–509 (2011).
   PubMed Web of Science ®Google Scholar
• Gao S , MobleyA, MillerC, BoklanJ, ChandraJ. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leuk. Res.32(5) , 771–780 (2008).
   PubMed Web of Science ®Google Scholar
• Gojo I , JiemjitA, TrepelJBet al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109(7) , 2781–2790 (2007).
   PubMed Web of Science ®Google Scholar
• Blum KA , AdvaniA, FernandezLet al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br. J. Haematol. 147(4) , 507–514 (2009).
   PubMed Web of Science ®Google Scholar
• Inoue S , MaiA, DyerMJ, CohenGM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res.66(13) , 6785–6792 (2006).
   PubMed Web of Science ®Google Scholar
• Vernarecci S , TosiF, FileticiP. Tuning acetylated chromatin with HAT inhibitors: a novel tool for therapy. Epigenetics5(2) , 105–111 (2010).
   PubMed Web of Science ®Google Scholar
• Bowers EM , YanG, MukherjeeCet al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17(5) , 471–482 (2010).
   PubMedGoogle Scholar
• Ott M , VerdinE. HAT trick: p300, small molecule, inhibitor. Chem. Biol.17(5) , 417–418 (2010).
   PubMedGoogle Scholar
• Mori S , IwaseK, IwanamiN, TanakaY, KagechikaH, HiranoT. Development of novel bisubstrate-type inhibitors of histone methyltransferase SET7/9. Bioorg. Med. Chem.18(23) , 8158–8166 (2010).
   PubMed Web of Science ®Google Scholar
• Greiner D , BonaldiT, EskelandR, RoemerE, ImhofA. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3–9. Nat. Chem. Biol.1(3) , 143–145 (2005).
   PubMed Web of Science ®Google Scholar
• Iwasa E , HamashimaY, FujishiroSet al. Total synthesis of (+)-chaetocin and its analogues: their histone methyltransferase G9a inhibitory activity. J. Am. Chem. Soc. 132(12) , 4078–4079 (2010).
   PubMed Web of Science ®Google Scholar
• Lakshmikuttyamma A , ScottSA, DecoteauJF, GeyerCR. Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene29(4) , 576–588 (2010).
   PubMed Web of Science ®Google Scholar
• Kubicek S , O‘SullivanRJ, AugustEMet al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell. 25(3) , 473–481 (2007).
   PubMed Web of Science ®Google Scholar
• Chang Y , ZhangX, HortonJRet al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat. Struct. Mol. Biol. 16(3) , 312–317 (2009).
   PubMed Web of Science ®Google Scholar
• Chang Y , GaneshT, HortonJRet al. Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J. Mol. Biol. 400(1) , 1–7 (2010).
   PubMed Web of Science ®Google Scholar
• Liu F , ChenX, Allali-HassaniAet al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J. Med. Chem. 52(24) , 7950–7953 (2009).
   PubMed Web of Science ®Google Scholar
• Liu F , ChenX, Allali-HassaniAet al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J. Med. Chem. 53(15) , 5844–5857 (2010).
   PubMed Web of Science ®Google Scholar
• Tan J , YangX, ZhuangLet al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9) , 1050–1063 (2007).
   PubMed Web of Science ®Google Scholar
• Fiskus W , WangY, SreekumarAet al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114(13) , 2733–2743 (2009).
   PubMed Web of Science ®Google Scholar
• Lee MG , WynderC, SchmidtDM, McCaffertyDG, ShiekhattarR. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol.13(6) , 563–567 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidt DM , MccaffertyDG. Trans-2-phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry46(14) , 4408–4416 (2007).
   PubMed Web of Science ®Google Scholar
• Mimasu S , UmezawaN, SatoS, HiguchiT, UmeharaT, YokoyamaS. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry49(30) , 6494–6503 (2010).
   PubMed Web of Science ®Google Scholar
• Binda C , ValenteS, RomanenghiMet al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J. Am. Chem. Soc. 132(19) , 6827–6833 (2010).
   PubMed Web of Science ®Google Scholar
• Szewczuk LM , CulhaneJC, YangM, MajumdarA, YuH, ColePA. Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. Biochemistry46(23) , 6892–6902 (2007).
   PubMed Web of Science ®Google Scholar
• Ueda R , SuzukiT, MinoKet al. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J. Am. Chem. Soc. 131(48) , 17536–17537 (2009).
   PubMed Web of Science ®Google Scholar
• Sharma SK , WuY, SteinbergsNet al. (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. J. Med. Chem. 53(14) , 5197–5212 (2010).
   PubMed Web of Science ®Google Scholar
• Hou H , YuH. Structural insights into histone lysine demethylation. Curr. Opin. Struct. Biol.20(6) , 739–748 (2010).
   PubMed Web of Science ®Google Scholar
• Hamada S , SuzukiT, MinoKet al. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. J. Med. Chem. 53(15) , 5629–5638 (2010).
   PubMed Web of Science ®Google Scholar
• King ON , LiXS, SakuraiMet al. Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS ONE 5(11) , e15535 (2010).
   PubMed Web of Science ®Google Scholar
• Rose NR , WoonEC, KinghamGLet al. Selective inhibitors of the JMJD2 histone demethylases: combined nondenaturing mass spectrometric screening and crystallographic approaches. J. Med. Chem. 53(4) , 1810–1818 (2010).
   PubMed Web of Science ®Google Scholar
• Winter J , DiederichsS. MicroRNA biogenesis and cancer. Methods Mol. Biol.676 , 3–22 (2011).
   PubMedGoogle Scholar
• Kusenda B , MrazM, MayerJ, PospisilovaS. MicroRNA biogenesis, functionality and cancer relevance. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.150(2) , 205–215 (2006).
   PubMedGoogle Scholar
• Gregory RI , ShiekhattarR. MicroRNA biogenesis and cancer. Cancer Res.65(9) , 3509–3512 (2005).
   PubMed Web of Science ®Google Scholar
• Cortez MA , IvanC, ZhouP, WuX, IvanM, CalinGA. MicroRNAs in cancer: from bench to bedside. Adv. Cancer Res.108 , 113–157 (2010).
   PubMed Web of Science ®Google Scholar
• Kloosterman WP , PlasterkRH. The diverse functions of microRNAs in animal development and disease. Dev. Cell11(4) , 441–450 (2006).
   PubMed Web of Science ®Google Scholar
• Ambros V . The functions of animal microRNAs. Nature431(7006) , 350–355 (2004).
   PubMed Web of Science ®Google Scholar
• Barbarotto E , SchmittgenTD, CalinGA. MicroRNAs and cancer: profile, profile, profile. Int. J. Cancer122(5) , 969–977 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao H , WangD, DuW, GuD, YangR. MicroRNA and leukemia: tiny molecule, great function. Crit. Rev. Oncol. Hematol.74(3) , 149–155 (2010).
   PubMed Web of Science ®Google Scholar
• Vasilatou D , PapageorgiouS, PappaV, PapageorgiouE, DervenoulasJ. The role of microRNAs in normal and malignant hematopoiesis. Eur. J. Haematol.84(1) , 1–16 (2010).
   PubMed Web of Science ®Google Scholar
• Cimmino A , CalinGA, FabbriMet al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102(39) , 13944–13949 (2005).
   PubMed Web of Science ®Google Scholar
• Calin GA , FerracinM, CimminoAet al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353(17) , 1793–1801 (2005).
   PubMed Web of Science ®Google Scholar
• Pekarsky Y , SantanamU, CimminoAet al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 66(24) , 11590–11593 (2006).
   PubMed Web of Science ®Google Scholar
• Fulci V , ChiarettiS, GoldoniMet al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109(11) , 4944–4951 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu DX , MiaoKR, FangCet al. Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. Leuk. Res. 35(6) , 730–734 (2010).
   PubMed Web of Science ®Google Scholar
• Ricci F , TedeschiA, MorraE, MontilloM. Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther. Clin. Risk Manag.5(1) , 187–207 (2009).
   PubMedGoogle Scholar
• Moussay E , PalissotV, VallarLet al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol. Cancer 9 , 115 (2010).
   PubMed Web of Science ®Google Scholar
• Ferracin M , ZagattiB, RizzottoLet al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol. Cancer 9 , 123 (2010).
   PubMed Web of Science ®Google Scholar
• Zenz T , MohrJ, ElderingEet al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113(16) , 3801–3808 (2009).
   PubMed Web of Science ®Google Scholar
• Mraz M , MalinovaK, KotaskovaJet al. miR-34a, miR-29c and miR-17–5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 23(6) , 1159–1163 (2009).
   PubMed Web of Science ®Google Scholar
• Asslaber D , PinonJD, SeyfriedIet al. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 115(21) , 4191–4197 (2010).
   PubMed Web of Science ®Google Scholar
• Rossi S , ShimizuM, BarbarottoEet al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116(6) , 945–952 (2010).
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B , MeulemanN, Haibe-KainsBet al. MicroRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 113(21) , 5237–5245 (2009).
   PubMed Web of Science ®Google Scholar
• Venturini L , BattmerK, CastoldiMet al. Expression of the miR-17–92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 109(10) , 4399–4405 (2007).
   PubMed Web of Science ®Google Scholar
• Bueno MJ , Perez de Castro I, Gomez de Cedron M et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell13(6) , 496–506 (2008).
   PubMed Web of Science ®Google Scholar
• Flamant S , RitchieW, GuilhotJet al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 95(8) , 1325–1333 (2010).
   PubMed Web of Science ®Google Scholar
• San Jose-Eneriz E , Roman-GomezJ, Jimenez-VelascoAet al. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol. Cancer 8 , 69 (2009).
   PubMed Web of Science ®Google Scholar
• Jongen-Lavrencic M , SunSM, DijkstraMK, ValkPJ, LowenbergB. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood111(10) , 5078–5085 (2008).
   PubMed Web of Science ®Google Scholar
• Li Z , LuJ, SunMet al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc. Natl Acad. Sci. USA 105(40) , 15535–15540 (2008).
   PubMed Web of Science ®Google Scholar
• Garzon R , GarofaloM, MartelliMPet al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc. Natl Acad. Sci. USA 105(10) , 3945–3950 (2008).
   PubMed Web of Science ®Google Scholar
• Isken F , SteffenB, MerkSet al. Identification of acute myeloid leukaemia associated microRNA expression patterns. Br. J. Haematol. 140(2) , 153–161 (2008).
   PubMed Web of Science ®Google Scholar
• Brioschi M , FischerJ, CairoliRet al. Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits. Neoplasia 12(11) , 866–876 (2010).
   PubMed Web of Science ®Google Scholar
• Pulikkan JA , PeramangalamPS, DenglerVet al. C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood 116(25) , 5638–5649 (2010).
   PubMed Web of Science ®Google Scholar
• Marcucci G , MaharryK, RadmacherMDet al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a cancer and leukemia group B study. J. Clin. Oncol. 26(31) , 5078–5087 (2008).
   PubMed Web of Science ®Google Scholar
• Marcucci G , RadmacherMD, MaharryKet al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358(18) , 1919–1928 (2008).
   PubMed Web of Science ®Google Scholar
• Debernardi S , SkoulakisS, MolloyG, ChaplinT, Dixon-McIverA, YoungBD. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia21(5) , 912–916 (2007).
   PubMed Web of Science ®Google Scholar
• Vazquez I , MaicasM, MarcoteguiNet al. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia. Proc. Natl Acad. Sci. USA 107(44) , E167–168; author reply E169–E170 (2010).
   PubMed Web of Science ®Google Scholar
• Mi S , LuJ, SunMet al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc. Natl Acad. Sci. USA 104(50) , 19971–19976 (2007).
   PubMed Web of Science ®Google Scholar
• Schotte D , ChauJC, SylvesterGet al. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia 23(2) , 313–322 (2009).
   PubMed Web of Science ®Google Scholar
• Schotte D , De Menezes RX, Akbari Moqadam F et al. MicroRNAs characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica96(5) , 703–711 (2011).
   PubMed Web of Science ®Google Scholar
• Garzon R , PichiorriF, PalumboTet al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 26(28) , 4148–4157 (2007).
   PubMed Web of Science ®Google Scholar
• Hammond SM . MicroRNA therapeutics: a new niche for antisense nucleic acids. Trends Mol. Med.12(3) , 99–101 (2006).
   PubMed Web of Science ®Google Scholar
• Lanford RE , Hildebrandt-EriksenES, PetriAet al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962) , 198–201 (2010).
   PubMed Web of Science ®Google Scholar
• Gao SM , ChenC, WuJet al. Synergistic apoptosis induction in leukemic cells by miR-15a/16–11 and arsenic trioxide. Biochem. Biophys. Res. Commun. 403(2) , 203–208 (2010).
   PubMed Web of Science ®Google Scholar
• Gu J , ZhuX, LiYet al. miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med. Oncol. 28(1) , 211–218 (2011).
   PubMed Web of Science ®Google Scholar
• Hu H , LiY, GuJet al. Antisense oligonucleotide against miR-21 inhibits migration and induces apoptosis in leukemic K562 cells. Leuk. Lymphoma 51(4) , 694–701 (2010).
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J , AgirreX, Jimenez-VelascoAet al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J. Clin. Oncol. 27(8) , 1316–1322 (2009).
   PubMed Web of Science ®Google Scholar
• Folmer F , OrlikovaB, SchnekenburgerM, DicatoM, DiederichM. Naturally occurring regulators of histone acetylation/deacetylation. Curr. Nutr. Food Sci.6 , 78–99 (2010).
   Google Scholar
• Link A , BalaguerF, GoelA. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem. Pharmacol.80(12) , 1771–1792 (2010).
   PubMed Web of Science ®Google Scholar
• vel Szic KS , NdlovuMN, HaegemanG, Vanden Berghe W. Nature or nurture: let food be your epigenetic medicine in chronic inflammatory disorders. Biochem. Pharmacol.80(12) , 1816–1832 (2010).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G , DanielJ, SmithTLet al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin. Cancer Res. 8(7) , 2217–2224 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor KH , Pena-HernandezKE, DavisJWet al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 67(6) , 2617–2625 (2007).
   PubMed Web of Science ®Google Scholar
• Issa JP , KantarjianH, MohanAet al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood 93(6) , 2075–2080 (1999).
   PubMed Web of Science ®Google Scholar
• Rahmatpanah FB , CarstensS, HooshmandSIet al. Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. Epigenomics 1(1) , 39–61 (2009).
   PubMed Web of Science ®Google Scholar
• Kuang SQ , TongWG, YangHet al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22(8) , 1529–1538 (2008).
   PubMed Web of Science ®Google Scholar
• Mulero-Navarro S , Carvajal-GonzalezJM, HerranzMet al. The dioxin receptor is silenced by promoter hypermethylation in human acute lymphoblastic leukemia through inhibition of Sp1 binding. Carcinogenesis 27(5) , 1099–1104 (2006).
   PubMed Web of Science ®Google Scholar
• Dunwell T , HessonL, RauchTAet al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol. Cancer 9 , 44 (2010).
   PubMed Web of Science ®Google Scholar
• Taniguchi H , FernandezAF, SetienFet al. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res. 69(21) , 8447–8454 (2009).
   PubMed Web of Science ®Google Scholar
• Murai M , ToyotaM, SatohAet al. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br. J. Cancer 92(6) , 1165–1172 (2005).
   PubMed Web of Science ®Google Scholar
• Scardocci A , GuidiF, D‘AloFet al. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br. J. Cancer 95(8) , 1108–1113 (2006).
   PubMed Web of Science ®Google Scholar
• Ritter M , de Kant E, Huhn D, Neubauer A. Detection of DNA methylation in the calcitonin gene in human leukemias using differential polymerase chain reaction. Leukemia9(5) , 915–921 (1995).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G , YangH, KuangSQ, O‘BrienS, ThomasD, KantarjianH. Epigenetics of acute lymphocytic leukemia. Semin. Hematol.46(1) , 24–32 (2009).
   PubMed Web of Science ®Google Scholar
• Takahashi T , ShivapurkarN, ReddyJet al. DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin. Cancer Res. 10(9) , 2928–2935 (2004).
   PubMed Web of Science ®Google Scholar
• Matsushita C , YangY, TakeuchiSet al. Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia. Oncol Rep. 12(1) , 97–99 (2004).
   PubMed Web of Science ®Google Scholar
• Ekmekci CG , GutierrezMI, SirajAK, OzbekU, BhatiaK. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am. J. Hematol.77(3) , 233–240 (2004).
   PubMed Web of Science ®Google Scholar
• San Jose-Eneriz E , AgirreX, Roman-GomezJet al. Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter. Br. J. Haematol. 134(2) , 137–144 (2006).
   PubMed Web of Science ®Google Scholar
• Wang YL , QianJ, LinJet al. Methylation status of DDIT3 gene in chronic myeloid leukemia. J. Exp. Clin. Cancer Res. 29 , 54 (2010).
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J , CordeuL, AgirreXet al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 109(8) , 3462–3469 (2007).
   PubMed Web of Science ®Google Scholar
• Yao J , HuangQ, ZhangXB, FuWL. Promoter CpG methylation of oestrogen receptors in leukaemia. Biosci. Rep.29(4) , 211–216 (2009).
   PubMed Web of Science ®Google Scholar
• Uhm KO , LeeES, LeeYMet al. Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia. J. Korean Med. Sci. 24(3) , 493–497 (2009).
   PubMed Web of Science ®Google Scholar
• Hoshino K , Quintas-CardamaA, YangH, Sanchez-GonzalezB, Garcia-ManeroG. Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia21(5) , 906–911 (2007).
   PubMed Web of Science ®Google Scholar
• Pallasch CP , PatzM, ParkYJet al. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 114(15) , 3255–3264 (2009).
   PubMed Web of Science ®Google Scholar
• Chim CS , WongKY, LeungCYet al. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J. Cell Mol. Med. DOI: 0.1111/j.1582-4934.2011.01274.x. (2011) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Kroeger H , JelinekJ, EstecioMRet al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112(4) , 1366–1373 (2008).
   PubMed Web of Science ®Google Scholar
• Montiel-Duarte C , CordeuL, AgirreXet al. Resistance to imatinib mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leuk. Res. 32(5) , 709–716 (2008).
   PubMed Web of Science ®Google Scholar
• Della Peruta M , MartinelliG, MorattiEet al. Protein tyrosine phosphatase receptor type {γ} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. Cancer Res. 70(21) , 8896–8906 (2010).
   PubMed Web of Science ®Google Scholar
• Hesson LB , DunwellTL, CooperWNet al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol. Cancer 8 , 42 (2009).
   PubMed Web of Science ®Google Scholar
• Bechter OE , EistererW, DlaskaM, KuhrT, ThalerJ. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp. Hematol.30(1) , 26–33 (2002).
   PubMed Web of Science ®Google Scholar
• Chantepie SP , VaurD, GrunauCet al. ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia. Leuk. Res. 34(6) , 800–808 (2010).
   PubMed Web of Science ®Google Scholar
• Marton S , GarciaMR, RobelloCet al. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 22(2) , 330–338 (2008).
   PubMed Web of Science ®Google Scholar
• Akao Y , NakagawaY, KitadeY, KinoshitaT, NaoeT. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci.98(12) , 1914–1920 (2007).
   PubMed Web of Science ®Google Scholar
• Frenquelli M , MuzioM, ScielzoCet al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 115(19) , 3949–3959 (2010).
   PubMed Web of Science ®Google Scholar
• Cardinaud B , MoreilhonC, MarcetBet al. miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia? Leukemia 23(11) , 2174–2177 (2009).
   PubMed Web of Science ®Google Scholar
• Agirre X , Jimenez-VelascoA, San Jose-Eneriz E et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol. Cancer Res.6(12) , 1830–1840 (2008).
   PubMed Web of Science ®Google Scholar
• Chapiro E , RussellLJ, StruskiSet al. A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia 24(7) , 1362–1364 (2010).
   PubMed Web of Science ®Google Scholar
• Bousquet M , HarrisMH, ZhouB, LodishHF. MicroRNA miR-125b causes leukemia. Proc. Natl Acad. Sci. USA107(50) , 21558–21563 (2010).
   PubMed Web of Science ®Google Scholar
• Tassano E , AcquilaM, TavellaE, MicalizziC, PanarelloC, MorerioC. MicroRNA-125b-1 and BLID upregulation resulting from a novel IGH translocation in childhood B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer49(8) , 682–687 (2010).
   PubMed Web of Science ®Google Scholar
• Zanette DL , RivadaviaF, MolfettaGAet al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz. J. Med. Biol. Res. 40(11) , 1435–1440 (2007).
   PubMed Web of Science ®Google Scholar
• Bhatia S , KaulD, VarmaN. Potential tumor suppressive function of miR-196b in B-cell lineage acute lymphoblastic leukemia. Mol. Cell Biochem.340(1–2) , 97–106 (2010).
   PubMed Web of Science ®Google Scholar
• Careccia S , MainardiS, PelosiAet al. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene 28(45) , 4034–4040 (2009).
   PubMed Web of Science ®Google Scholar
• Garzon R , VoliniaS, LiuCGet al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111(6) , 3183–3189 (2008).
   PubMed Web of Science ®Google Scholar
• Li Z , LuoRT, MiSet al. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res. 69(3) , 1109–1116 (2009).
   PubMed Web of Science ®Google Scholar
• Mi S , LiZ, ChenPet al. Aberrant overexpression and function of the miR-17–92 cluster in MLL-rearranged acute leukemia. Proc. Natl Acad. Sci. USA 107(8) , 3710–3715 (2010).
   PubMed Web of Science ®Google Scholar
• Wong P , IwasakiM, SomervailleTCet al. The miR-17–92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res. 70(9) , 3833–3842 (2010).
   PubMed Web of Science ®Google Scholar
• Gao XN , LinJ, LiYHet al. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene 30(31) , 3416–3428 (2011).
   PubMed Web of Science ®Google Scholar
• Popovic R , RiesbeckLE, VeluCSet al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 113(14) , 3314–3322 (2009).
   PubMed Web of Science ®Google Scholar
• Ramsingh G , KoboldtDC, TrissalMet al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood 116(24) , 5316–5326 (2010).
   PubMed Web of Science ®Google Scholar
• Liu S , WuLC, PangJet al. Sp1/NFκB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 17(4) , 333–347 (2010).
   PubMed Web of Science ®Google Scholar
• Paluszczak J , Krajka-KuzniakV, Baer-DubowskaW. The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol. Lett.192(2) , 119–125 (2010).
   PubMed Web of Science ®Google Scholar
• Li Y , VandenboomTG 2nd, Kong D et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res.69(16) , 6704–6712 (2009).
   PubMed Web of Science ®Google Scholar
• Wang LG , LiuXM, FangYet al. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int. J. Oncol. 33(2) , 375–380 (2008).
   PubMed Web of Science ®Google Scholar
• Nair S , HebbarV, ShenGet al. Synergistic effects of a combination of dietary factors sulforaphane and (-) epigallocatechin-3-gallate in HT-29 AP-1 human colon carcinoma cells. Pharm. Res. 25(2) , 387–399 (2008).
   PubMed Web of Science ®Google Scholar
• Myzak MC , TongP, DashwoodWM, DashwoodRH, HoE. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp. Biol. Med. (Maywood)232(2) , 227–234 (2007).
   PubMed Web of Science ®Google Scholar
• Li Y , LiX, GuoB. Chemopreventive agent 3,3´-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res.70(2) , 646–654 (2010).
   PubMed Web of Science ®Google Scholar
• Mai A , RotiliD, TarantinoDet al. Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J. Med. Chem. 49(23) , 6897–6907 (2006).
   PubMed Web of Science ®Google Scholar
• Balasubramanyam K , SwaminathanV, RanganathanA, KunduTK. Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem.278(21) , 19134–19140 (2003).
   PubMed Web of Science ®Google Scholar
• Eliseeva ED , ValkovV, JungM, JungMO. Characterization of novel inhibitors of histone acetyltransferases. Mol. Cancer Ther.6(9) , 2391–2398 (2007).
   PubMed Web of Science ®Google Scholar
• Sung B , PandeyMK, AhnKSet al. Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-κB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-κBα kinase, leading to potentiation of apoptosis. Blood 111(10) , 4880–4891 (2008).
   PubMed Web of Science ®Google Scholar
• Bora-Tatar G , Dayangac-ErdenD, DemirAS, DalkaraS, YelekciK, Erdem-YurterH. Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: activity and docking studies. Bioorg. Med. Chem.17(14) , 5219–5228 (2009).
   PubMed Web of Science ®Google Scholar
• Waldecker M , KautenburgerT, DaumannH, BuschC, SchrenkD. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J. Nutr. Biochem.19(9) , 587–593 (2008).
   PubMed Web of Science ®Google Scholar
• Tan S , WangC, LuCet al. Quercetin is able to demethylate the p16INK4a gene promoter. Chemotherapy 55(1) , 6–10 (2009).
   PubMed Web of Science ®Google Scholar
• Howitz KT , BittermanKJ, CohenHYet al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425(6954) , 191–196 (2003).
   PubMed Web of Science ®Google Scholar
• Wood JG , RoginaB, LavuSet al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430(7000) , 686–689 (2004).
   PubMed Web of Science ®Google Scholar
• Ruiz PA , BrauneA, HolzlwimmerG, Quintanilla-FendL, HallerD. Quercetin inhibits TNF-induced NF-κB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells. J. Nutr.137(5) , 1208–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Lee WJ , ZhuBT. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis27(2) , 269–277 (2006).
   PubMed Web of Science ®Google Scholar
• Arif M , PradhanSK, ThanujaGRet al. Mechanism of p300 specific histone acetyltransferase inhibition by small molecules. J. Med. Chem. 52(2) , 267–277 (2009).
   PubMed Web of Science ®Google Scholar
• Nian H , DelageB, PintoJT, DashwoodRH. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis29(9) , 1816–1824 (2008).
   PubMed Web of Science ®Google Scholar
• Lea MA , RasheedM, RandolphVM, KhanF, ShareefA, DesbordesC. Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine. Nutr. Cancer43(1) , 90–102 (2002).
   PubMed Web of Science ®Google Scholar
• Druesne N , PagniezA, MayeurCet al. Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 25(7) , 1227–1236 (2004).
   PubMed Web of Science ®Google Scholar
• Gracia-Sancho J , VillarrealG Jr, Zhang Y, Garcia-Cardena G. Activation of SIRT1 by resveratrol induces KLF2 expression conferring an endothelial vasoprotective phenotype. Cardiovasc. Res.85(3) , 514–519 (2010).
   PubMed Web of Science ®Google Scholar
• Kaeberlein M , McdonaghT, HeltwegBet al. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 280(17) , 17038–17045 (2005).
   PubMed Web of Science ®Google Scholar
• Yang J , KongX, Martins-SantosMEet al. Activation of SIRT1 by resveratrol represses transcription of the gene for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) by deacetylating hepatic nuclear factor 4α. J. Biol. Chem. 284(40) , 27042–27053 (2009).
   PubMed Web of Science ®Google Scholar
• Boily G , HeXH, PearceB, JardineK, McburneyMW. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene28(32) , 2882–2893 (2009).
   PubMed Web of Science ®Google Scholar
• Tsao AS , LiuD, MartinJet al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev. Res. (Phila.) 2(11) , 931–941 (2009).
   PubMed Web of Science ®Google Scholar
• Choi KC , JungMG, LeeYHet al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 69(2) , 583–592 (2009).
   PubMed Web of Science ®Google Scholar
• Balasubramanian S , AdhikaryG, EckertRL. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Carcinogenesis31(3) , 496–503 (2010).
   PubMed Web of Science ®Google Scholar
• Tsang WP , KwokTT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J. Nutr. Biochem.21(2) , 140–146 (2010).
   PubMed Web of Science ®Google Scholar
• Fang MZ , ChenD, SunY, JinZ, ChristmanJK, YangCS. Reversal of hypermethylation and reactivation of p16INK4a, RARβ, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res.11(19 Pt 1) , 7033–7041 (2005).
   PubMed Web of Science ®Google Scholar
• Majid S , DarAA, AhmadAEet al.BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis30(4) , 662–670 (2009).
   PubMed Web of Science ®Google Scholar
• Tang WY , NewboldR, MardilovichKet al. Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology 149(12) , 5922–5931 (2008).
   PubMed Web of Science ®Google Scholar
• King-Batoon A , LeszczynskaJM, KleinCB. Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ. Mol. Mutagen.49(1) , 36–45 (2008).
   PubMed Web of Science ®Google Scholar
• Liu Z , XieZ, JonesWet al. Curcumin is a potent DNA hypomethylation agent. Bioorg. Med. Chem. Lett. 19(3) , 706–709 (2009).
   PubMed Web of Science ®Google Scholar
• Chen Y , ShuW, ChenW, WuQ, LiuH, CuiG. Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor κB and Notch 1 in Raji cells. Basic Clin. Pharmacol. Toxicol.101(6) , 427–433 (2007).
   PubMed Web of Science ®Google Scholar
• Marcu MG , JungYJ, LeeSet al. Curcumin is an inhibitor of p300 histone acetylatransferase. Med. Chem. 2(2) , 169–174 (2006).
   PubMed Web of Science ®Google Scholar
• Chiu J , KhanZA, FarhangkhoeeH, ChakrabartiS. Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-κB. Nutrition25(9) , 964–972 (2009).
   PubMed Web of Science ®Google Scholar
• Sun M , EstrovZ, JiY, CoombesKR, HarrisDH, KurzrockR. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer. Ther.7(3) , 464–473 (2008).
   PubMed Web of Science ®Google Scholar
• Ali S , AhmadA, BanerjeeSet al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 70(9) , 3606–3617 (2010).
   PubMed Web of Science ®Google Scholar

▪ Website

• Clinical Trial Database www.clinicaltrial.gov
   Google Scholar